Deutsch
EnglishEinen Kommentar schreiben zu Web Forum Reader
Kommentare zu Web Forum Reader
Seite auswählen: Anfang | Zurück | …3,4,5,6,7,8… | Weiter | Ende
ArianGok aus ArianGok schrieb am 12.01.2017:
книгу на 50 оттенков свободы epub песню александр рыбак fairytale на русском решебник к русскому языку 2 класс бунеев контрольные работы 10-11 класс по геометрии бланк заявления на прикрепление к поликлинике нижний новгород песни в исполнении челентано карту naruto arena для warcraft 3 frozen throne фильм легенда о призраке в хорошем качестве фильм трансформеры 4 лучшие игры на андроид закон о физической культуре и спорте в рф программу daemon tools lite для windows xp дидактические материалы по алгебре 8 класс потапов наргиз ты моя нежность winrar бесплатная версия на русском языке http://xenla.ru/bia46cv/?p=412 http://xenla.ru/ax9taptpj/?p=850 http://xenla.ru/7d6n9/?p=149 http://xenla.ru/wm1ebf1/?p=510 http://xenla.ru/biq5em/?p=887 http://xenla.ru/pmbc7s1n/?p=504 http://xenla.ru/a2gxwd/?p=579 http://xenla.ru/w135bgen/?p=772 http://xenla.ru/7ed7a7k3/?p=260 http://xenla.ru/3puwba/?p=280 http://xenla.ru/cdoc0/?p=794 http://xenla.ru/kc2vw2e0/?p=199 http://xenla.ru/pbf6p/?p=640 http://xenla.ru/7i4tdzox/?p=93 http://xenla.ru/o5pyzhp1/?p=225
CurtisPr aus CurtisPr schrieb am 28.12.2016:
irpozcu
http://www.urbanislam.nl/
http://www.monasortagard.se/
http://www.ponypack.nl/
http://www.spdtwente.nl/
http://www.kolonieteller.nl/
[url=http://www.freiwilligenagentur-meppen.de]ugg boots outlet[/url]
[url=http://www.cayle.ca/]belstaff canada[/url]
[url=http://www.gsmzoeker.be/]timberland antwerpen[/url]
[url=http://www.prolaendle.at/]moncler jacken[/url]
[url=http://www.dierenpensionwansink.nl/]uggs dames[/url]
RonaldEn aus RonaldEn schrieb am 28.12.2016:
kjedguf
http://www.gameswallpapers.eu/996-adidas-tubular-発売日.html
http://www.rockstarschool.es/996-zapatos-adidas-de-mujeres.php
http://www.gameswallpapers.eu/183-アディダスãƒã‚ª-レディース-スニーカー.html
http://www.institut-lili.fr/934-chaussure-nike-running-noir.htm
http://www.sabrinaglas.de/nike-air-max-1-schuhe-farbe-rot-weiß-braun-832.html
[url=http://www.northside1994.it/superstar-bianche-e-nere-511.php]Superstar Bianche E Nere[/url]
[url=http://www.womenambassadors.it/air-max-estive-uomo-056.php]Air Max Estive Uomo[/url]
[url=http://www.cigarrilloselectronicosmadrid.es/773-nike-huarache-beige.htm]Nike Huarache Beige[/url]
[url=http://www.gameswallpapers.eu/675-laトレーナー-コーディãƒãƒ¼ãƒˆ.html]Laトレーナー コーディãƒãƒ¼ãƒˆ[/url]
[url=http://www.cigarrilloselectronicosmadrid.es/359-nike-presto-dama.htm]Nike Presto Dama[/url]
CurtisPr aus CurtisPr schrieb am 03.12.2016:
vdstdrf
http://www.responsabilidadmedica.es/
http://www.hosting-prestashop.es
http://www.pintorespontevedra.es/
http://www.chinavibratoryhammer.es/
http://www.terrazasdemadera.es/
[url=http://www.terrazasdemadera.es/]levitra sin receta[/url]
[url=http://www.pharmaceutical-care.es/]kamagra sin receta[/url]
[url=http://www.responsabilidadmedica.es/]viagra sin receta[/url]
[url=http://www.hosting-prestashop.es]cialis prospecto[/url]
[url=http://www.mantenimientodejardines.com.es/]levitra original[/url]
DouglasFep aus DouglasFep schrieb am 26.11.2016:
kadakwt
http://www.herdephotos.fr/368-adidas-yeezy-rouge-et-noir.html
http://www.fuschiasoaps.co.uk/nike-air-huarache-womens-red-006.html
http://www.cigarrilloselectronicosmadrid.es/947-air-max-thea-oferta.html
http://www.soomland.nl/740-nike-huarache-grijs-bestellen.html
http://www.fuschiasoaps.co.uk/nike-air-huarache-black-womens-250.html
[url=http://www.fuschiasoaps.co.uk/nike-air-force-1-high-grey-118.htm]Nike Air Force 1 High Grey[/url]
[url=http://www.cigarrilloselectronicosmadrid.es/038-air-force-one-mujer-baratas.htm]Air Force One Mujer Baratas[/url]
[url=http://www.kiosk-am-lechfall.de/608-nike-dunkelblau.htm]Nike Dunkelblau[/url]
[url=http://www.womenambassadors.it/air-max-command-pelle-189.php]Air Max Command Pelle[/url]
[url=http://www.gameswallpapers.eu/053-スーパースター-é´.html]スーパースター é´[/url]
RichardBobe aus RichardBobe schrieb am 24.11.2016:
sitvioo
http://www.m12359.com
http://www.m12356.com
http://www.m12357.com
[url=http://www.m12359.com/]m12359[/url]
[url=http://www.m12356.com/]m12356[/url]
[url=http://www.m12357.com/]m12357[/url]
Groverst aus Groverst schrieb am 15.08.2016:
ООО РОССтехнология предлагает услуги по нанесению САП "БИУРС",протегол,РПУ-1001 и РПУ1021,скочкоут и др. полимеров и мастик методом безвоздушного напыления на фасонные изделия, запорную арматуру и трубы различного диаметра для КС (ДКС), НПС, переизоляция линейной части газонефтепроводов и др.
г.Екатеринбург, ул.Восточная, 10 Телефон:8(343)269-80-09. http://aksonural.ru/
Производит работы по устройству:
монолитной, надежной, долговечной и высокопрочной кровли,а также ремонт старого кровельного покрытия/методом спекания/;
антиобледенительной системы «крыша без сосулек», обогрев водостоков;
антикоррозионой обработке любых покрытий.
напыление
пенополиуретан,
полимочевина,
жидкая резина
aaronanderson aus aaronanderson schrieb am 20.11.2015:
Coumadin is also used to treat these conditions if they develop. The most common side effects of Coumadin are easy bruising and bleeding, nausea, vomiting, stomach pain, bloating, gas, or altered sense of taste.
Coumadin has a wide range of tablets: 2, 2.5, 3, 4, 5, 6, 7.5 and 10 mg tablets are available. An injectable form of the drug (5 mg) is also available. The dose of Coumadin is determined in each individual by administering a trial dose and ten measuring the patient's INR (International Normalized Ratio), a lab test that is standardized by the WHO (world Health Organization) and recognized worldwide. Therapeutic ranges for this test are between 2.0 to 3.0 when a patient is taking Coumadin. INR levels below 2 may allow easier blood clotting to occur while levels above 3 may cause excessive tendency for the patient to bleed. Several different Coumadin doses and INR tests (over 1-4 weeks) are usually necessary to establish a relatively stable and therapeutic INR level in each individual. Unfortunately, there are at least 60 different drugs that may increase or decrease the body's ability to utilize Coumadin any the majority of people that need Coumadin are often require one or more of these drugs; this situation also is why each Coumadin dose is individualized. The major risk factor with Coumadin is hemorrhage. Small emboli may occasionally be released while on Coumadin, causing "purple toes;" although this may be reversible, a few patients may develop gangrene. Pregnant women should not be given Coumadin; lactating women may need to be closely monitored and their breastfed infants should have their INR checked, according to some investigators. Although Coumadin has been used in pediatric patients to prevent clot formations, children under 18 have not been well studied with this drug and some investigators suggest achieving stable INR levels seems more difficult in the pediatric population.
Our [url=http://claricefoxworthyohz.soup.io/post/642308100/Coumadin]Coumadin kaufen rezeptfrei[/url] Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication. SIDE EFFECTS: Nausea, loss of appetite, or stomach/abdominal pain may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.
Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.
This medication can cause serious bleeding if it affects your blood clotting proteins too much (shown by unusually high INR lab results). Even if your doctor stops your medication, this risk of bleeding can continue for up to a week. Tell your doctor right away if you have any signs of serious bleeding, including: unusual pain/swelling/discomfort, unusual/easy bruising, prolonged bleeding from cuts or gums, persistent/frequent nosebleeds, unusually heavy/prolonged menstrual flow, pink/dark urine, coughing up blood, vomit that is bloody or looks like coffee grounds, severe headache, dizziness/fainting, unusual or persistent tiredness/weakness, bloody/black/tarry stools, chest pain, shortness of breath, difficulty swallowing.
Tell your doctor right away if any of these unlikely but serious side effects occur: persistent nausea/vomiting, severe stomach/abdominal pain, yellowing eyes/skin.
This drug rarely has caused very serious (possibly fatal) problems if its effects lead to small blood clots (usually at the beginning of treatment). This can lead to severe skin/tissue damage that may require surgery or amputation if left untreated. Patients with certain blood conditions (protein C or S deficiency) may be at greater risk. Get medical help right away if any of these rare but serious side effects occur: painful/red/purplish patches on the skin (such as on the toe, breast, abdomen), change in the amount of urine, vision changes, confusion, slurred speech, weakness on one side of the body.
A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.
This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist. What is the most important information I should know about Coumadin (Coumadin, Jantoven)?
Follow your doctor's instructions about taking Coumadin while you are pregnant. Coumadin can harm an unborn baby or cause birth defects. However, the benefits of preventing blood clots in certain women may outweigh any risks to the baby.
Never take a double dose of this medication.
You should not take Coumadin if you have a bleeding or blood cell disorder, blood in your urine or stools, an infection of the lining of your heart, stomach bleeding, bleeding in the brain, recent or upcoming surgery, or if you need a spinal tap or spinal anesthesia (epidural).
Coumadin may cause you to bleed more easily, especially if you have: a history of bleeding problems, high blood pressure or severe heart disease, kidney or liver disease, cancer, surgery or a medical emergency, a disease affecting the blood vessels in your brain, a history of stomach or intestinal bleeding, if you are 65 or older, or if you are severely ill or debilitated.
Many drugs (including some over-the-counter medicines and herbal products) can cause serious medical problems or death if you take them with Coumadin. It is very important to tell your doctor about all medicines you have recently used.
Any doctor, dentist, surgeon, or other medical care provider who treats you should know that you are taking this medication.
aaronanderson aus aaronanderson schrieb am 29.10.2015:
In adult patients with liver or renal impairment, a starting dose of one 5-mg tablet every other day is recommended based on pharmacokinetic data.
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
Adults and Adolescents
Allergic Rhinitis: In multiple-dose placebo-controlled trials, 2834 patients ages 12 years or older received Clarinex Tablets at doses of 2.5 mg to 20 mg daily, of whom 1655 patients received the recommended daily dose of 5 mg. In patients receiving 5 mg daily, the rate of adverse events was similar between Clarinex and placebo-treated patients. The percent of patients who withdrew prematurely due to adverse events was 2.4% in the Clarinex group and 2.6% in the placebo group. There were no serious adverse events in these trials in patients receiving desloratadine. All adverse events that were reported by greater than or equal to 2% of patients who received the recommended daily dose of [url=http://raquelursiak4t.tumblr.com/post/132142739694/clarinex-was-approved]Clarinex Preis[/url]
Tablets (5 mg once daily), and that were more common with Clarinex Tablets than placebo, are listed in
Pediatrics
Two hundred and forty-six pediatric subjects 6 months to 11 years of age received Clarinex Oral Solution for 15 days in three placebo-controlled clinical trials. Pediatric subjects aged 6 to 11 years received 2.5 mg once a day, subjects aged 1 to 5 years received 1.25 mg once a day, and subjects 6 to 11 months of age received 1.0 mg once a day.
In subjects 6 to 11 years of age, no individual adverse event was reported by 2 percent or more of the subjects.
In subjects 2 to 5 years of age, adverse events reported for Clarinex and placebo in at least 2 percent of subjects receiving Clarinex Oral Solution and at a frequency greater than placebo were fever (5.5%, 5.4%), urinary tract infection (3.6%, 0%) and varicella (3.6%, 0%).
In subjects 12 months to 23 months of age, adverse events reported for the Clarinex product and placebo in at least 2 percent of subjects receiving Clarinex Oral Solution and at a frequency greater than placebo were fever (16.9%, 12.9%), diarrhea (15.4%, 11.3%), upper respiratory tract infections (10.8%, 9.7%), coughing (10.8%, 6.5%), appetite increased (3.1%, 1.6%), emotional lability (3.1%, 0%), epistaxis (3.1%, 0%), parasitic infection (3.1%, 0%), pharyngitis (3.1%, 0%), rash maculopapular (3.1%, 0%).
In subjects 6 months to 11 months of age, adverse events reported for Clarinex and placebo in at least 2 percent of subjects receiving Clarinex Oral Solution and at a frequency greater than placebo were upper respiratory tract infections (21.2%, 12.9%), diarrhea (19.7%, 8.1%), fever (12.1%, 1.6%), irritability (12.1%, 11.3%), coughing (10.6%, 9.7%), somnolence (9.1%, 8.1%), bronchitis (6.1%, 0%), otitis media (6.1%, 1.6%), vomiting (6.1%, 3.2%), anorexia (4.5%, 1.6%), pharyngitis (4.5%, 1.6%), insomnia (4.5%, 0%), rhinorrhea (4.5%, 3.2%), erythema (3.0%, 1.6%), and nausea (3.0%, 0%).
There were no clinically meaningful changes in any electrocardiographic parameter, including the QTc interval. Only one of the 246 pediatric subjects receiving Clarinex Oral Solution in the clinical trials discontinued treatment because of an adverse event.
Post-Marketing Experience
Because adverse events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following spontaneous adverse events have been reported during the marketing of desloratadine: tachycardia, palpitations, rare cases of hypersensitivity reactions (such as rash, pruritus, urticaria, edema, dyspnea, and anaphylaxis), psychomotor hyperactivity, movement disorders (including dystonia, tics, and extrapyramidal symptoms), seizures, and elevated liver enzymes including bilirubin, and very rarely, hepatitis.
Inhibitors of Cytochrome P450 3A4
In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3).]
Fluoxetine
In controlled clinical studies co-administration of desloratadine with fluoxetine, a selective serotonin reuptake inhibitor (SSRI), resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3).]
Cimetidine
In controlled clinical studies co-administration of desloratadine with cimetidine, a histamine H2-receptor antagonist, resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3).]
USE IN SPECIFIC POPULATIONS
Pregnancy
Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, desloratadine should be used during pregnancy only if clearly needed.
Desloratadine was not teratogenic in rats or rabbits at approximately 210 and 230 times, respectively, the area under the concentration-time curve (AUC) in humans at the recommended daily oral dose. An increase in pre-implantation loss and a decreased number of implantations and fetuses were noted, however, in a separate study in female rats at approximately 120 times the AUC in humans at the recommended daily oral dose. Reduced body weight and slow righting reflex were reported in pups at approximately 50 times or greater than the AUC in humans at the recommended daily oral dose. Desloratadine had no effect on pup development at approximately 7 times the AUC in humans at the recommended daily oral dose. The AUCs in comparison referred to the desloratadine exposure in rabbits and the sum of desloratadine and its metabolites exposures in rats, respectively. [See Nonclinical Toxicology (13.2).]
Nursing Mothers
Desloratadine passes into breast milk; therefore, a decision should be made whether to discontinue nursing or to discontinue desloratadine, taking into account the benefit of the drug to the nursing mother and the possible risk to the child.
Pediatric Use
The recommended dose of Clarinex Oral Solution in the pediatric population is based on cross-study comparison of the plasma concentration of Clarinex in adults and pediatric subjects. The safety of Clarinex Oral Solution has been established in 246 pediatric subjects aged 6 months to 11 years in three placebo-controlled clinical studies. Since the course of seasonal and perennial allergic rhinitis and chronic idiopathic urticaria and the effects of Clarinex are sufficiently similar in the pediatric and adult populations, it allows extrapolation from the adult efficacy data to pediatric patients. The effectiveness of Clarinex Oral Solution in these age groups is supported by evidence from adequate and well-controlled studies of Clarinex Tablets in adults. The safety and effectiveness of Clarinex Tablets or Clarinex Oral Solution have not been demonstrated in pediatric patients less than 6 months of age. [See Clinical Pharmacology (12.3).]
The Clarinex RediTabs 2.5-mg tablet has not been evaluated in pediatric patients.
Geriatric Use
Other reported clinical experience has not identified differences between the elderly and younger patients.
aaronbailey aus aaronbailey schrieb am 29.10.2015:
The active component of SEREVENT DISKUS is salmeterol xinafoate, a beta2- adrenergic bronchodilator. Salmeterol xinafoate is the racemic form of the 1-hydroxy-2- naphthoic acid salt of salmeterol. It has the chemical name 4-hydroxy-a1-[[[6-(4- phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol, 1-hydroxy-2- naphthalenecarboxylate and the following chemical structure:
SEREVENT DISKUS (salmeterol xinafoate inhalation powder) Structural Formula Illustration
Salmeterol xinafoate is a white powder with a molecular weight of 603.8, and the empirical formula is C25H37NO4•C11H8O3. It is freely soluble in methanol; slightly soluble in ethanol, chloroform, and isopropanol; and sparingly soluble in water.
SEREVENT DISKUS is a teal green plastic inhaler containing a foil blister strip. Each blister on the strip contains a white powder mix of micronized salmeterol xinafoate salt (72.5 mcg, equivalent to 50 mcg of salmeterol base) in 12.5 mg of formulation containing lactose monohydrate (which contains milk proteins). After the inhaler is activated, the powder is dispersed into the airstream created by the patient inhaling through the mouthpiece.
Under standardized in vitro test conditions, SEREVENT DISKUS delivers 47 mcg of salmeterol base per blister when tested at a flow rate of 60 L/min for 2 seconds.
In adult subjects with obstructive lung disease and severely compromised lung function (mean FEV1 20% to 30% of predicted), mean peak inspiratory flow (PIF) through a DISKUS® inhaler was 82.4 L/min (range: 46.1 to 115.3 L/min).
The actual amount of drug delivered to the lung will depend on patient factors, such as inspiratory flow profile.
What are the possible side effects of salmeterol inhalation (Serevent Diskus)?
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:
chest pain, fast or pounding heartbeats, tremors, shaking, or restless feeling;
skin rash, bruising, severe tingling, numbness, pain, muscle weakness;
wheezing, choking, or other breathing problems after using this medication; or
worsening asthma symptoms.
Less serious side effects may...
Read All Potential Side Effects and See Pictures of [url=http://yourevochkabovkunova.tumblr.com/post/132139981401/what-is-serevent]Serevent Preis[/url]
Diskus »
What are the precautions when taking salmeterol xinafoate (Serevent Diskus)?
Before using this medication, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.
Before using this drug, tell your doctor or pharmacist your medical history, especially of: heart problems (e.g., angina, irregular heartbeat), high blood pressure, diabetes, liver problems, seizures, thyroid problems (e.g., overactive thyroid).
Salmeterol may cause a condition that affects the heart rhythm (QT prolongation). QT prolongation can infrequently result in serious (rarely fatal) fast/irregular heartbeat and other symptoms (such as severe dizziness, fainting) that need medical attention right.
Treatment Of Asthma
SEREVENT DISKUS is indicated for the treatment of asthma and in the prevention of bronchospasm only as concomitant therapy with a long-term asthma control medication, such as an inhaled corticosteroid, in patients aged 4 years and older with reversible obstructive airway disease, including patients with symptoms of nocturnal asthma. LABA, such as salmeterol, the active ingredient in SEREVENT DISKUS, increase the risk of asthma-related death [see WARNINGS AND PRECAUTIONS]. Use of SEREVENT DISKUS for the treatment of asthma without concomitant use of a long-term asthma control medication, such as an inhaled corticosteroid, is contraindicated [see CONTRAINDICATIONS]. Use SEREVENT DISKUS only as additional therapy for patients with asthma who are currently taking but are inadequately controlled on a long-term asthma control medication, such as an inhaled corticosteroid. Once asthma control is achieved and maintained, assess the patient at regular intervals and step down therapy (e.g., discontinue SEREVENT DISKUS) if possible without loss of asthma control and maintain the patient on a long-term asthma control medication, such as an inhaled corticosteroid. Do not use SEREVENT DISKUS for patients whose asthma is adequately controlled on low- or medium-dose inhaled corticosteroids.
Pediatric and Adolescent Patients
For pediatric and adolescent patients with asthma who require addition of a LABA to an inhaled corticosteroid, a fixed-dose combination product containing both an inhaled corticosteroid and a LABA should ordinarily be used to ensure adherence with both drugs.
Important Limitation of Use
SEREVENT DISKUS is NOT indicated for the relief of acute bronchospasm.
Prevention Of Exercise-Induced Bronchospasm
SEREVENT DISKUS is also indicated for prevention of exercise-induced bronchospasm (EIB) in patients aged 4 years and older. Use of SEREVENT DISKUS as a single agent for the prevention of EIB may be clinically indicated in patients who do not have persistent asthma. SEREVENT DISKUS is indicated for the long-term twice-daily administration in the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD) (including emphysema and chronic bronchitis).